Physician

Muhammad R. Abbasi, M.D.

According to 2025 Medicare claims, Muhammad Abbasi, M.D. (NPI: 1245349638) practices hematology/oncology in the Newark, NJ market, with the plurality of this provider's patient population coming from Morris, NJ. This provider's primary affiliated billing organization is ONCOLOGY & HEMATOLOGY SPECIALISTS,P.A. (NPI: 1962511147; TIN: 222132567) and primary practice location at 07046-1601.

Abbasi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 490 traditional Medicare patients, billed 144,466 HCPCS/CPT codes, and received $3,398,606 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 448 prescription claims across 133 beneficiaries totaling $661,154 in drug costs, led by Procrit (Epoetin Alfa). DME data shows 12 claims. Open Payments data shows 118 records totaling $2,822. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,622,866 to $3,398,606. In contrast, Part D prescription costs have moved from a higher plateau to a lower plateau, from $3,220,206 to $661,154. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	863	167,380	$1,622,866
2016	693	159,207	$1,933,539
2017	721	143,730	$1,806,134
2018	643	202,292	$2,394,769
2019	627	176,493	$2,379,152
2020	502	148,503	$2,120,840
2021	509	179,244	$2,958,816
2022	484	137,783	$3,307,919
2023	490	138,802	$3,121,137
2024	490	144,466	$3,398,606

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	175	1,272	$3,220,206
2016	175	1,295	$3,907,847
2017	177	1,294	$3,908,568
2018	176	972	$2,787,520
2019	161	636	$1,041,294
2020	146	516	$742,565
2021	133	445	$355,182
2022	140	461	$692,861
2023	133	510	$801,277
2024	133	448	$661,154

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	66	$5,649
2016	N/R	12	$416
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	27	$2,933
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	12	$226

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	97	97	$185
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	412	1,766	$107
96372	Injection of drug or substance under skin or into muscle	93	729	$12
36415	Insertion of needle into vein for collection of blood sample	406	1,828	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	401	1,784	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Procrit	Epoetin Alfa	22	616	$73,314
Eliquis	Apixaban	52	1,673	$32,376
Xarelto	Rivaroxaban	39	1,383	$25,489
Anastrozole	Anastrozole	52	3,390	$847
Folic Acid	Folic Acid	30	2,710	$270

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	12	$226

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	118	$2,822	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Muhammad R. Abbasi, M.D.?

Tedicare shows public-source Medicare data for Muhammad R. Abbasi, M.D. (NPI 1245349638), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Muhammad R. Abbasi, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Muhammad R. Abbasi, M.D.?

Muhammad R. Abbasi, M.D. is linked to ONCOLOGY & HEMATOLOGY SPECIALISTS,P.A. (billing NPI 1962511147) in the available physician profile data.

Does Muhammad R. Abbasi, M.D. have Open Payments data?

Muhammad R. Abbasi, M.D. has 118 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.